| Identification | Back Directory | [Name]
N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide | [CAS]
211311-95-4 | [Synonyms]
100775
CS-2739
LY404187
LY-404187; LY 404187
N-2-(4-(4-Cyanophenyl)phenyl)propyl-2-propanesulfonamide
N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide
N-[2-[4-(4-Cyanophenyl)phenyl]propyl]propane-2-sulfonamide
N-[2-(4'-Cyano[1,1'-biphenyl]-4-yl)propyl]-2-propanesulfonamide
N-(2-(4'-Cyano-[1,1'-biphenyl]-4-yl)propyl)propane-2-sulfonaMide
2-Propanesulfonamide, N-[2-(4'-cyano[1,1'-biphenyl]-4-yl)propyl]-
LY-404187 N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide | [Molecular Formula]
C19H22N2O2S | [MDL Number]
MFCD07364003 | [MOL File]
211311-95-4.mol | [Molecular Weight]
342.46 |
| Chemical Properties | Back Directory | [Boiling point ]
519.0±60.0 °C(Predicted) | [density ]
1.19±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DMF: 15mg/mL; DMSO: 15mg/mL; DMSO:PBS (pH 7.2) (1:4): 0.2mg/mL; Ethanol: 3mg/mL | [form ]
A solid | [pka]
11.24±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
LY404187 is a benzothiadiazide positive allosteric modulator of AMPA receptors. It increases glutamate-induced activation of GluR1i, -2i, -2o, -3i, and -4i subunit-containing AMPA receptors with EC50 values of 5.65, 0.15, 1.44, 1.66, and 0.21 μM, respectively, in a calcium influx assay. LY404187 is selective for these AMPA receptors over GluR6 subunit-containing kainate receptors at 10 μM. LY404187 increases currents induced by glutamate and AMPA in rat prefrontal cortex pyramidal neurons (EC50s = 1.3 and 1.2 μM, respectively) but not in AMPA-stimulated primary rat embryonic hippocampal or primary cerebellar Purkinje neurons. LY404187 prevents decreases in the number of dopaminergic neurons in the substantia nigra induced by MPTP and 6-OHDA in mouse and rat, respectively, models of Parkinson’s disease when administered at a dose of 0.5 mg/kg per day. | [Uses]
LY 404187 is a novel positive allosteric modulator of AMPA receptors. | [in vivo]
LY-404187 (0.5 mg/kg; s.c for 11 days) can prevent MPTP-induced neurotoxicity in mice[4].
LY-404187 (0.5 mg/kg; s.c. for 28 days) attenuates apomorphine-induced contraversive rotations and affords significant protection against the loss of tyrosine hydroxylase positive nigral cell bodies[4].
LY-404187 (0.1 or 0.5 mg/kg; s.c. for 14 days) affords functional, neurochemical and histological protection after infusion of 6-hydroxydopamine into the substantia nigra in rats[4].
LY-404187 (0.5 mg/kg; s.c. for 14 days) delayed treatment provides functional and histological improvement, suggesting a trophic action as administration is initiated after cell death[4].
LY-404187 (0.1 and 0.5 mg/kg; s.c. for 14 days) increases GAP-43 immunoreactivity in the striatum in a dose-dependent manner[4]. | Animal Model: | Male C57BL/6J mice (20-25 g) are challenged with MPTP on day 8[4] | | Dosage: | 0.5 mg/kg | | Administration: | S.c; twice daily on weekdays and once daily at weekends for 11 days | | Result: | Attenuated the loss of tyrosine hydroxylase immunoreactivity in the substantia nigra.
No significant change in tyrosine hydroxylase immunoreactivity in the dorsal and ventral striatum.
|
| [storage]
Store at +4°C |
|
| Company Name: |
ChemShuttle, Inc.
|
| Tel: |
0150-83588313-811 18800520310 |
| Website: |
www.jiehuapharma.com/ |
|